54 peer-reviewed studies · Evidence score: 8.5/10
Nakahara T et al. • Molecular psychiatry (2022)
Increased glutamatergic metabolite levels and reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.
Tariq S et al. • Brain and behavior (2023)
Despite limitations, dopamine antagonists can serve as first-line agents in SC management, followed by antiepileptics.
Liu J et al. • The Cochrane database of systematic reviews (2018)
This review provides moderate-quality evidence that fails to support the use of GABA receptor agonists (chlormethiazole or diazepam) for the treatment of people with acute stroke.
Rissardo JP et al. • Medicina (Kaunas, Lithuania) (2025)
Based on the main clinical constellation of symptoms and pathophysiological mechanisms found in this study, DIM can be categorized into three types: type 1 (serotonin syndrome), type 2 (non-serotonin syndrome), and type 3 (unknown).
Rømer TB et al. • Molecular psychiatry (2023)
The Author(s), under exclusive licence to Springer Nature Limited.
Thomson AR et al. • Neuroscience and biobehavioral reviews (2024)
Data were extracted and grouped by metabolite, brain region and several other factors before calculation of standardised effect sizes.
Diana A et al. • The Cochrane database of systematic reviews (2017)
According to high-quality evidence, gabapentin is not effective in treating ALS.
Azargoonjahromi A • Nutrition reviews (2024)
The results provide plausible evidence for the positive role of zinc in the treatment of patients afflicted with anxiety, albeit with some limitations.
Carello-Collar G et al. • Molecular psychiatry (2023)
The Author(s), under exclusive licence to Springer Nature Limited.
Zou J et al. • Psychiatry research (2023)
The percentages of patients with PPD achieving Hamilton Depression Rating Scale (HAM-D) response and remission were significantly higher after brexanolone or zuranolone administration compared with...
Hepsomali P et al. • Nutrients (2020)
Oral GABA supplementation showed benefits for stress reduction and sleep quality across reviewed clinical trials.
Bruni O et al. • Nutrients (2021)
Currently available evidence suggests that herbal extracts may exert some of their hypnotic and anxiolytic activity through interacting with GABA receptors and modulating GABAergic signaling in the brain, but their mechanism of action in the treatment of insomnia is not completely understood.
Alabed S et al. • The Cochrane database of systematic reviews (2018)
We are uncertain about the evidence of the effects of baclofen, progabide, sodium valproate or tetrahydroisoxazolopyridinol (THIP) for people with antipsychotic-induced TD.
Miller N et al. • The Laryngoscope (2022)
The most promising potential uses for GABA analogues identified in this review are for improving swallowing, trismus, and narcotic overuse after RT.
Guo CY et al. • Current opinion in neurology (2020)
High clinical suspicion and early diagnosis are important given the potential for clinical improvement with immunotherapy.
McKay JH et al. • Neurologia i neurochirurgia polska (2019)
GABAB-R autoimmune disease is characterized by refractory seizures or status epilepticus and frequent association with small cell lung cancer.
Warburton E et al. • BMJ clinical evidence (2011)
We performed a GRADE evaluation of the quality of evidence for interventions.
Romeo B et al. • Journal of psychiatry & neuroscience : JPN (2018)
The GABA levels evolved differentially in patients with unipolar and bipolar disorders.
Stallman HM et al. • Sleep medicine reviews (2018)
All other associations were based on case reports.
Younis S et al. • Current opinion in neurology (2017)
Nevertheless, to identify a biomarker in migraine, MRS may be a valuable noninvasive technique.